Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00723099 · OUTCOME

Percent of Patients With Non-relapse Mortality

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer · Source last updated 2019-12-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent of patients
Interval / dispersion
Not reported
Time frame
1 year

What was measured

Kaplan-Meier and cumulative incidence estimates

Groups in this outcome

Treatment (Chemotherapy, Transplant)

CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients with low risk of graft failure (multi-agent chemotherapy in the last 3 months or history of autologous transplant) receive 200cGy TBI on day -1. Patients with high risk of graft failure receive 300 cGy TBI on day -1. UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0. IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96. Allogeneic Hematopoietic Stem Cell Transplantation: Undergo umbilical cord blood transplant

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Chemotherapy, Transplant)72

Reported measurements

Source class 1
Values in percent of patients · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Chemotherapy, Transplant)38Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        38
denoms
  1. counts
    1. group Id
      OG000
      value
      72
    units
    Participants
description
Kaplan-Meier and cumulative incidence estimates
groups
  1. description
    CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients with low risk of graft failure (multi-agent chemotherapy in the last 3 months or history of autologous transplant) receive 200cGy TBI on day -1. Patients with high risk of graft failure receive 300 cGy TBI on day -1. UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0. IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96. Allogeneic Hematopoietic Stem Cell Transplantation: Undergo umbilical cord blood transplant
    id
    OG000
    title
    Treatment (Chemotherapy, Transplant)
param Type
NUMBER
reporting Status
POSTED
time Frame
1 year
title
Percent of Patients With Non-relapse Mortality
type
SECONDARY
unit Of Measure
percent of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice